BioCardia Signs Exclusive Development Agreement With AstraZeneca
BioCardia, Inc. (BCDA)
US:NASDAQ Investor Relations:
biocardia.com/investors/press-releases/id/1037?pressreleaseid=41
Company Research
Source: GlobeNewswire
SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system. Under the terms of the initial pre-clinical phase of the relationship, BioCardia will receive a sizable upfront payment, a portion of which will be creditable to BioCardia biotherapeutic delivery systems, support and training. The agreement is exclusive with respect to a class of biotherapeutic agents that BioCardia is not currently developing on its own or with any other party and is time limited. “We are delighted to continue our collaboration with AstraZeneca, a world-class therapeutics leader,” said BioCardia CEO Peter Altman, PhD. “As we advance our own CardiAMP cell therapy clinical programs that benefit from delivery with our Helix
Show less
Read more
Impact Snapshot
Event Time:
BCDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCDA alerts
High impacting BioCardia, Inc. news events
Weekly update
A roundup of the hottest topics
BCDA
News
- BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]Yahoo! Finance
- BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]Yahoo! Finance
- BioCardia Reports Third Quarter 2024 Business Highlights and Financial ResultsGlobeNewswire
BCDA
Earnings
- 8/13/24 - Miss
BCDA
Sec Filings
- 11/19/24 - Form 4
- 11/13/24 - Form 8-K
- 11/13/24 - Form 10-Q
- BCDA's page on the SEC website